Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Total Non-Current Liabilities (2017 - 2023)

Denali Therapeutics has reported Total Non-Current Liabilities over the past 7 years, most recently at $123.0 million for Q4 2023.

  • Quarterly Total Non-Current Liabilities fell 70.54% to $123.0 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $123.0 million through Dec 2023, down 70.54% year-over-year, with the annual reading at $123.0 million for FY2023, 70.54% down from the prior year.
  • Total Non-Current Liabilities was $123.0 million for Q4 2023 at Denali Therapeutics, up from $118.1 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $453.0 million in Q4 2020 and troughed at $118.1 million in Q3 2023.
  • The 5-year median for Total Non-Current Liabilities is $295.0 million (2020), against an average of $289.1 million.
  • Year-over-year, Total Non-Current Liabilities skyrocketed 201.41% in 2021 and then plummeted 71.61% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $158.0 million in 2019, then skyrocketed by 186.81% to $453.0 million in 2020, then decreased by 2.55% to $441.5 million in 2021, then dropped by 5.45% to $417.4 million in 2022, then plummeted by 70.54% to $123.0 million in 2023.
  • Per Business Quant, the three most recent readings for DNLI's Total Non-Current Liabilities are $123.0 million (Q4 2023), $118.1 million (Q3 2023), and $118.5 million (Q2 2023).